Selective O-GlcNAcase Inhibitors for Tau Hyperphosphorylation
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current inhibitors for blocking O-GlcNAcase function are non-selective, affecting both O-GlcNAcase and related β-hexosaminidases, leading to complex phenotypes and unintended cellular effects.
Innovation Solution
Development of selective compounds that inhibit O-GlcNAcase activity without significantly affecting β-hexosaminidases, specifically targeting O-GlcNAcase to modulate O-GlcNAc levels and prevent tau hyperphosphorylation and associated neurodegenerative effects.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If non-selective inhibitors are used to block O-GlcNAcase function, then O-GlcNAc levels are elevated and tau hyperphosphorylation is reduced, but β-hexosaminidases are also inhibited causing complex phenotypes and unintended cellular effects
Solution Approach 1:
The patent applies local quality by designing inhibitors with specific molecular structures that selectively bind to O-GlcNAcase active site characteristics. The compounds contain functional groups and spatial arrangements that match the unique structural features of O-GlcNAcase, allowing selective inhibition without affecting β-hexosaminidases. This enables targeted elevation of O-GlcNAc levels on tau protein while avoiding non-specific inhibition of other glycosidases.
Solution Approach 2:
The patent employs parameter changes by modifying chemical parameters of inhibitor compounds to achieve selective binding. By adjusting molecular weight, functional groups, stereochemistry, and binding affinity parameters, the inhibitors are optimized to recognize O-GlcNAcase specifically. The compounds exhibit particular kinetic parameters (Km, Ki values) that differentiate their interaction with O-GlcNAcase versus β-hexosaminidases, enabling selective inhibition.
2Reliability
If O-GlcNAcase is inhibited to prevent tau hyperphosphorylation, then neurodegenerative processes are reduced, but selectivity must be maintained to avoid affecting other hexosaminidases
Solution Approach 1:
The patent applies segmentation by dividing the glycosidase enzyme family into distinct functional categories (O-GlcNAcase versus β-hexosaminidases) and designing inhibitors that target only the O-GlcNAcase segment. The molecular structure of the inhibitors contains specific segments or moieties that recognize unique features of O-GlcNAcase, allowing selective binding while leaving β-hexosaminidases unaffected. This segmented approach enables therapeutic efficacy through selective inhibition.
Solution Approach 2:
The patent uses intermediary principles by introducing small molecule compounds as mediators that specifically bridge the interaction between the drug delivery system and O-GlcNAcase. These intermediary compounds act as selective blockers that can be administered systemically, traverse biological barriers, and selectively inhibit O-GlcNAcase in the brain without requiring direct delivery of complex therapeutic agents. The intermediaries translate systemic administration into selective local inhibition.
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
The selective inhibitors effectively elevate O-GlcNAc levels, reducing tau hyperphosphorylation and neurodegenerative processes, offering a therapeutic approach for Alzheimer's disease and related tauopathies while minimizing impact on other hexosaminidases.
Implementation Method 1
The selective inhibitors effectively elevate O-GlcNAc levels, reducing tau hyperphosphorylation
Implementation Method 2
O-GlcNAc modification has been found to occur on many proteins at amino acid residues that are also known to be phosphorylated
Data Source
AI summary
The invention is directed to compounds for selectively inhibiting glycosidases, uses of the compounds and pharmaceutical compositions including the compounds, and methods of treating diseases and disorders related to deficiency or overexpression of O-GlcNAcase, and/or accumulation or deficiency of O-GlcNAc.